Amphastar Pharmaceuticals Reports Net Revenues of $56.9 Million for the First Quarter Ended March 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Jefferies Remains Bullish Following Amphastar Pharma's (AMPH) Strong Q1
May 14, 2015 10:27 AM EDTJefferies maintains a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), and raised the price target to $19.00 (from $18.00), after a strong Q1. Analyst David Steinberg said that the strong Q1 was driven by a better than expected top line.
Steinberg commented on AMPH, saying, "Posting sales of $27.1M (+37% Y/Y), AMPHs base IMS injectables business contributed to half of the Q1 rev upside relative to our est, largely reflecting price... More
Amphastar Pharma (AMPH) Reports Q1 Loss of 1c/Share
May 13, 2015 6:01 AM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of ($0.01), versus $0.00 reported last year. Revenue for the quarter came in at $56.89 million, versus $45.87 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More